Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00010322 · ClinicalTrials.gov registry record · Phase 3
Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer
A Phase 3 study, sponsored by Intarcia Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
NCT00010322: Clinical Trial Phase 3 study, sponsored by Intarcia Therapeutics.
NCT00010322 is a Phase 3 study that was terminated before completion, run by Intarcia Therapeutics. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00010322, a Phase 3 study, was terminated before completion, sponsored by Intarcia Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Toremifene may fight breast cancer by blocking the uptake of estrogen by the tumor cells. Atamestane may fight breast cancer by blocking the production of estrogen. It is not yet known if toremifene is more effective with or without atamestane. PURPOSE: Randomized phase III trial to compare the effectiveness of toremifene with or without atamestane in treating postmenopausal women who have metastatic breast cancer.
Interventions
- DRUG atamestane
- DRUG toremifene
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10 |
| Est. Completion | 2001-05 |
| Phase | Phase 3 |
Why NCT00010322 stopped before completion
NCT00010322 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which atamestane is the first listed.
NCT00010322 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00010322 about?
NCT00010322 is a clinical study titled "Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Toremifene may fight breast cancer by blocking the uptake of estrogen by the tumor cells. Atamestane may fight breast cancer by blocking the production of estrogen. It is not yet known if toremifene is more effective with or withou...
What is the current status of trial NCT00010322?
This trial is currently terminated. It is a Phase 3 study. The study started on 2000-10. Estimated completion is 2001-05.
What interventions are being tested in trial NCT00010322?
The interventions under investigation include: atamestane (DRUG), toremifene (DRUG).
Who is sponsoring clinical trial NCT00010322?
This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia